Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

How drugs are promoted isn’t a freedom of speech issue

PalMD
Meds
December 31, 2012
Share
Tweet
Share

I learned of a disturbing decision from the Court of Appeals for the Second Circuit. In an insane ruling, two of judges determined that a drug rep promoting “off-label” uses for a drug was exercising his freedom of speech. Let’s stroll to the back of a typical doctor’s office to see how this plays out.

Of all the ways pharmaceutical companies market drugs, two are especially distasteful (i.e. annoying, immoral, and dangerous). The first is direct-to-consumer advertising (“Having chest pain? Take Brand A aspirin! Oh, and call 911!) The other is the practice of drug company marketers (drug reps) visiting doctors’ offices.

In both cases, people whose job it is to sell a product are doing their best to get patients asking for a drug and doctors prescribing it. The drug companies argue that they are providing a necessary service: educating doctors about new drugs, the obvious fallacy being that their incentive isn’t to “educate” but to inculcate. One of the ways this practice has been regulated historically is by telling drug reps they can only promote the drug for uses approved by the FDA.

So, for example, if NewSuperDrug has been shown to improve hair growth, and that’s what the FDA has approved it for, a drug rep cannot (except perhaps in the Second Circuit) also say, “By the way, it’s also great for blood pressure. Give it a try.”

Here’s where it gets sticky. It may be true that the drug is good for blood pressure. A doctor may choose to prescribe it for that. But when it comes to marketing, the manufacturers have to stick to what they proved to the FDA (except perhaps in the Second Circuit).

This is bad—really bad. First of all, doctors shouldn’t be getting their information from drug reps. It’s hard enough parsing through the literature, with its publication biases, decline effect, and drug company shenanigans—hard, but not impossible. What’s not so hard is finding appropriate non-corporate-sponsored Continuing Medical Education (CME) credits. Conferences, websites, medical associations all give docs access to information, information less biased than that from the people who stand to benefit from your prescribing habits.

Drug reps are, by reputation, young, attractive, and sociable. They also tend to want to feed you. Many medical centers, especially the ones that participate in medical education, have banned drug reps. But doctors offices often let them in. (Full disclosure: we let them in, but don’t let them bring lunches. Certain drugs, like ALL asthma drugs, aren’t available as generics, and we need the samples.)

It’s hard for a doc like me to see how free speech enters into limiting what these folks can say. The obvious analogies (theater, fire, etc.) aren’t even needed. We regulate advertisers all the time, for example, prosecuting certain types of deception. Bait-and-switch advertising isn’t OK and we don’t see limiting it as an onerous imposition on free speech.

Drugs are pretty damned complicated and important. Telling drug companies they can’t promote their drugs except for the uses they managed to get approved is actually a good thing. Allowing them to say whatever they want gives them license to increase their sales by convincing busy doctors to prescribe for off-label uses that may or may not be OK. Yes, docs like me are supposed to know the difference, but studies have clearly shown that we are influenced by drug reps, whether we think so or not.

My advice: docs shouldn’t talk to drug reps. Cut of their access, and the companies will have to find other ways to promote their products. But since we can’t and probably shouldn’t prevent drug companies from marketing their products to doctors, we have to make it clear that this isn’t a free speech issue, but a safety and public health issue.

My guess would be that the current Supreme Court, where this case may end up, will think it’s just fine for drug reps to say whatever they want, so it’s time for doctors to stop listening.

“PalMD” is an internal medicine physician who blogs at White Coat Underground.

Image credit: Shutterstock.com

ADVERTISEMENT

Prev

How to foster generosity at an early age

December 31, 2012 Kevin 1
…
Next

It's time to rethink the role of antivirals in flu treatment

December 31, 2012 Kevin 2
…

Tagged as: Medications, Primary Care

Post navigation

< Previous Post
How to foster generosity at an early age
Next Post >
It's time to rethink the role of antivirals in flu treatment

ADVERTISEMENT

More by PalMD

  • Google doesn’t care about your health. See me instead.

    PalMD
  • From one doctor to another: “I don’t think we’re ever getting out of here.”

    PalMD
  • a desk with keyboard and ipad with the kevinmd logo

    Witness to a patient, losing her life in front of us

    PalMD

More in Meds

  • How deprescribing in psychiatry offers a path to safer care

    Muhamad Aly Rifai, MD
  • The economics of medical weight loss

    Howard Smith, MD
  • Why the cannabis ethics debate is really about human suffering

    Gerald Kuo
  • Testosterone cardiovascular risk: FDA update 2025

    Martina Ambardjieva, MD, PhD
  • Are you neurodivergent or just bored?

    Martha Rosenberg
  • Pharmacy benefit manager reform vs. direct drug plans

    Leah M. Howard, JD
  • Most Popular

  • Past Week

    • The loss of community pharmacy expertise

      Muhammad Abdullah Khan | Conditions
    • Accountable care cooperatives: a community-owned health care fix

      David K. Cundiff, MD | Policy
    • Psychiatrists are physicians: a key distinction

      Farid Sabet-Sharghi, MD | Physician
    • Why the expiration of ACA enhanced subsidies threatens health care access

      Sandya Venugopal, MD and Tina Bharani, MD | Policy
    • Is primary care becoming a triage station?

      J. Leonard Lichtenfeld, MD | Physician
    • A physician’s tribute to his medical technologist wife

      Ronald L. Lindsay, MD | Physician
  • Past 6 Months

    • Direct primary care in low-income markets

      Dana Y. Lujan, MBA | Policy
    • Patient modesty in health care matters

      Misty Roberts | Conditions
    • The U.S. gastroenterologist shortage explained

      Brian Hudes, MD | Physician
    • The Silicon Valley primary care doctor shortage

      George F. Smith, MD | Physician
    • California’s opioid policy hypocrisy

      Kayvan Haddadan, MD | Conditions
    • A lesson in empathy from a young patient

      Dr. Arshad Ashraf | Physician
  • Recent Posts

    • Is primary care becoming a triage station?

      J. Leonard Lichtenfeld, MD | Physician
    • Violence against physicians and the role of empathy

      Dr. R.N. Supreeth | Physician
    • The impact of policy cuts on ableism in health care

      Ahna Shome, MD | Policy
    • How deprescribing in psychiatry offers a path to safer care

      Muhamad Aly Rifai, MD | Meds
    • AI in prior authorization: the new gatekeeper

      Tiffiny Black, DM, MPA, MBA | Conditions
    • Why learning specialists are central to medical education [PODCAST]

      The Podcast by KevinMD | Podcast

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 24 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

ADVERTISEMENT

  • Most Popular

  • Past Week

    • The loss of community pharmacy expertise

      Muhammad Abdullah Khan | Conditions
    • Accountable care cooperatives: a community-owned health care fix

      David K. Cundiff, MD | Policy
    • Psychiatrists are physicians: a key distinction

      Farid Sabet-Sharghi, MD | Physician
    • Why the expiration of ACA enhanced subsidies threatens health care access

      Sandya Venugopal, MD and Tina Bharani, MD | Policy
    • Is primary care becoming a triage station?

      J. Leonard Lichtenfeld, MD | Physician
    • A physician’s tribute to his medical technologist wife

      Ronald L. Lindsay, MD | Physician
  • Past 6 Months

    • Direct primary care in low-income markets

      Dana Y. Lujan, MBA | Policy
    • Patient modesty in health care matters

      Misty Roberts | Conditions
    • The U.S. gastroenterologist shortage explained

      Brian Hudes, MD | Physician
    • The Silicon Valley primary care doctor shortage

      George F. Smith, MD | Physician
    • California’s opioid policy hypocrisy

      Kayvan Haddadan, MD | Conditions
    • A lesson in empathy from a young patient

      Dr. Arshad Ashraf | Physician
  • Recent Posts

    • Is primary care becoming a triage station?

      J. Leonard Lichtenfeld, MD | Physician
    • Violence against physicians and the role of empathy

      Dr. R.N. Supreeth | Physician
    • The impact of policy cuts on ableism in health care

      Ahna Shome, MD | Policy
    • How deprescribing in psychiatry offers a path to safer care

      Muhamad Aly Rifai, MD | Meds
    • AI in prior authorization: the new gatekeeper

      Tiffiny Black, DM, MPA, MBA | Conditions
    • Why learning specialists are central to medical education [PODCAST]

      The Podcast by KevinMD | Podcast

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

How drugs are promoted isn’t a freedom of speech issue
24 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...